Two new appointments at Eastbound Shanghai Institute
This article was originally published in Scrip
Eastbound Shanghai Institute, a subsidiary of Eastbound Synopharma (China), has appointed Dr Young Lo as research fellow, effective November 16th, and Chris Vance as vice-president for sales, marketing and business development. Dr Lo has more than 35 years' experience in chemical process development in the pharmaceutical industry, having previously worked at A H Robins, DuPont Merck and Boehringer Ingelheim. Mr Vance has more than 30 years of experience in the chemical and pharmaceutical industry, having formerly served as head of the sales and marketing team at Boehringer Ingelheim Chemicals.
You may also be interested in...
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.
Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.
The Belgian biotech has divested its drug discovery services unit in Croatia which was making a nice profit but was not a priority as Galapagos concentrates on setting up its commercial operations in Europe.